Bispecific HER2 antibodies

US10160812B2 · kind B2 · utility

Assignee

• MedImmune Limited · US

Inventors

• John Li · Lawrence, US
• Nazzareno Dimasi · Gaithersburg, US
• Steven Coats · Gaithersburg, US
• Melissa Damschroder · Gaithersburg, US
• Changshou Gao · Potomac, US
• Godfrey Jonah Anderson Rainey · Gaithersburg, US
• Cuihua Gao · Gaithersburg, US
• Dorin Toader · Cambridge, US
• Lakshmaiah Gingipalli · Waltham, US
• Fengjiang Wang · Northborough, US
• Ryan Fleming · Gaithersburg, US
• Binyam Bezabeh · Gaithersburg, US
• Andy Yuan · Gaithersburg, US
• Srinath Kasturirangan · Gaithersburg, US

Key dates

• Filing date: Apr 10, 2015
• Grant date: Dec 25, 2018
• Expiry date: Apr 10, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.